ArticleTherapeutic advances in medical oncology2025
Cost-effectiveness of perioperative durvalumab plus neoadjuvant chemotherapy for muscle invasive bladder cancer in the United States.
Caicong You et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.